{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:38:06Z","timestamp":1772851086459,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T00:00:00Z","timestamp":1600473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Foundation for Promotion of Cancer Research in Japan","award":["FPCR-2012-B"],"award-info":[{"award-number":["FPCR-2012-B"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00280-020-04147-4","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T08:03:53Z","timestamp":1600502633000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4657-0856","authenticated-orcid":false,"given":"Tomoko","family":"Morita-Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,19]]},"reference":[{"key":"4147_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2165\/00003088-199732040-00005","volume":"32","author":"E Masson","year":"1997","unstructured":"Masson E, Zamboni WC (1997) Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. ClinPharmacokinet 32:324\u2013343","journal-title":"ClinPharmacokinet"},{"key":"4147_CR2","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1038\/sj.bjc.6600139","volume":"86","author":"H Gurney","year":"2002","unstructured":"Gurney H (2002) How to calculate the dose of chemotherapy. Br J Cancer 86:1297\u20131302","journal-title":"Br J Cancer"},{"key":"4147_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.lungcan.2007.03.014","volume":"57","author":"J Jiang","year":"2007","unstructured":"Jiang J, Liang X, Zhou X et al (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348\u2013358","journal-title":"Lung Cancer"},{"key":"4147_CR4","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2004.02.109","volume":"22","author":"K Hotta","year":"2004","unstructured":"Hotta K, Matsuo K, Ueoka H et al (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852\u20133859","journal-title":"J Clin Oncol"},{"key":"4147_CR5","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310\u20132317","journal-title":"J Clin Oncol"},{"key":"4147_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","volume":"21","author":"DJ Adelstein","year":"2003","unstructured":"Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92\u201398","journal-title":"J Clin Oncol"},{"key":"4147_CR7","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068\u20133077","journal-title":"J Clin Oncol"},{"key":"4147_CR8","volume-title":"Physicians\u2019 cancer chemotherapy drug manual 2017","author":"E Chu","year":"2007","unstructured":"Chu E (2007) Physicians\u2019 cancer chemotherapy drug manual 2017. Jones and Bartlett Publishers, Massachusetts"},{"key":"4147_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/scipharm85010008","volume":"85","author":"T Hendrayana","year":"2017","unstructured":"Hendrayana T, Wilmer A, Kurth V et al (2017) Anticancer dose adjustment for patients with renal and hepatic dysfunction: from scientific evidence to clinical application. Sci Pharm 85:8\u201323","journal-title":"Sci Pharm"},{"key":"4147_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s10147-012-0481-x","volume":"18","author":"T Ogawa","year":"2013","unstructured":"Ogawa T, Niho S, Nagai S et al (2013) Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment. Int J Clin Oncol 18:977\u2013982","journal-title":"Int J Clin Oncol"},{"key":"4147_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s002800050548","volume":"39","author":"N Nagai","year":"1996","unstructured":"Nagai N, Kinoshita M, Ogata H et al (1996) Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. Cancer Chemother Pharmacol 39:131\u2013137","journal-title":"Cancer Chemother Pharmacol"},{"key":"4147_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0378-4347(00)83855-4","volume":"529","author":"M Kinoshita","year":"1990","unstructured":"Kinoshita M, Yoshimura N, Ogata H et al (1990) High-performance liquid chromatographic analysis of unchanged cis-diamminedichloroplatinum (cisplatin) in plasma and urine with post-columa derivatization. J Chromatogr 529:462\u2013467","journal-title":"J Chromatogr"},{"key":"4147_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0378-4347(94)00415-2","volume":"663","author":"K Hanada","year":"1995","unstructured":"Hanada K, Nagai N, Ogata H (1995) Quantitative determination of unchanged cisplatin in rat kidney and liver by high-performance liquid chromatograpy. J Chromatogr B 663:181\u2013186","journal-title":"J Chromatogr B"},{"key":"4147_CR14","first-page":"1025","volume":"38","author":"N Nagai","year":"1998","unstructured":"Nagai N, Ogata H, Wada Y et al (1998) Population pharmacokinetics and pharcodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J ClinPharmacol 38:1025\u20131034","journal-title":"J ClinPharmacol"},{"key":"4147_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/jjco\/hye040","volume":"31","author":"K Hanada","year":"2001","unstructured":"Hanada K, Nishijima K, Ogata H et al (2001) Population pharmacokinetic analysis of cisplatin and its metabolites in cancer patients: possible misinterpretation of covariates for pharmacokinetic parameters calculated from the concentrations of unchanged cisplatin, ultrafiltered platinum and total platinum. Jpn J Clin Oncol 31:179\u2013184","journal-title":"Jpn J Clin Oncol"},{"key":"4147_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.08.016","author":"JM Loh","year":"2017","unstructured":"Loh JM, Tran AL, Ji L et al (2017) Baseline glomerular filtration rate and cisplatin- induced renal toxicity in urothelial cancer patients. ClinGenitourin Cancer. https:\/\/doi.org\/10.1016\/j.clgc.2017.08.016","journal-title":"ClinGenitourin Cancer"},{"key":"4147_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398","journal-title":"N Engl J Med"},{"key":"4147_CR18","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","volume":"21","author":"F Fossella","year":"2003","unstructured":"Fossella F, Pereira JR, von Pawel J et al (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 21:3016\u20133024","journal-title":"J Clin Oncol"},{"key":"4147_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1200\/JCO.2004.06.114","volume":"22","author":"K Kubota","year":"2004","unstructured":"Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254\u2013261","journal-title":"J Clin Oncol"},{"key":"4147_CR20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11096-013-9912-7","volume":"36","author":"Y Bennis","year":"2014","unstructured":"Bennis Y, Savry A, Rocca M et al (2014) Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int J Clin Pharm 36:420\u2013429","journal-title":"Int J Clin Pharm"},{"key":"4147_CR21","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.2004.10.163","volume":"22","author":"H Minami","year":"2004","unstructured":"Minami H, Ohe Y, Niho S et al (2004) Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol 22:2901\u20132908","journal-title":"J Clin Oncol"},{"key":"4147_CR22","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/BF00257629","volume":"24","author":"PA Reece","year":"1989","unstructured":"Reece PA, Stafford I, Davy M et al (1989) Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer. Cancer Chemother Pharmacol 24:256\u2013260","journal-title":"Cancer Chemother Pharmacol"},{"key":"4147_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/JCO.1989.7.2.270","volume":"7","author":"PA Reece","year":"1989","unstructured":"Reece PA, Stafford I, Abbott RL et al (1989) Two-versus 24-hour infusion of cisplatin: pharmacokinetic considerations. J Clin Oncol 7:270\u2013275","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04147-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04147-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:40:36Z","timestamp":1632012036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04147-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,19]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4147"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04147-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,19]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Ethics Committee of the National Cancer Center approved this study (No. 2011-083).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Each patient provided written, informed consent to participate.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Each patient provided written, informed consent to participate.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data of patients enrolled in this analysis will not be used for secondary studies.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"None.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}